Efficacy, safety and immunogenicity of Soberana 02 vaccine (product of Finlay Institute): a double-blind, randomized, placebo-controlled phase III clinical trial : Efficacy, safety, and immunogenicity of Soberana recombinant vaccine (product of Finlay Institute) based on RBD protein subunit of Sars-Cov-2 in a 2-dose regimen with and without a booster dose: a double-blind, randomized, placebo-controlled phase III clinical trial in the Iranian population of 18-80 years

Medienart:

Klinische Studie

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

WHO International Clinical Trials Registry Platform - (2021) vom: 29. Nov. Zur Gesamtaufnahme - year:2021

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: Coronavirus Disease (COVID-19). Need for immunization against COVID-19
Recruitment Status: Completed
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2021-04-24, Last updated: 2022-11-24

ICTRP ID:

IRCT20210303050558N1

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG007651619